{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:19:32Z","timestamp":1765779572237,"version":"3.48.0"},"reference-count":21,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,25]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Uterine serous carcinoma (USC) accounts for 40% of endometrial cancer-related deaths. The standard of care for stages III and IV USC yields a 20%\u201330% survival at 2 years and a 10%\u201320% survival at 3\u20135 years. Recent advances in the second-line treatment of advanced or recurrent USC are rapidly evolving. Targeted therapeutic approaches with the use of lenvatinib plus pembrolizumab, as well as the use of trastuzumab deruxtecan, offer new hope for successful second-line therapies for patients. However, further investigation into novel targeted therapeutic approaches is warranted, given the high burden of disease associated with this aggressive histological subtype. USC shares clinical and genomic similarities with epithelial ovarian cancer, suggesting a correlation with \u2018BRCAness\u2019. Niraparib, a potent PARP1 and PARP2 inhibitor, was shown to have a positive impact on platinum-sensitive recurrent ovarian cancer, regardless of the presence or absence of BRCA status. Our hypothesis is that patients with stage III, stage IV and platinum-sensitive recurrent USC receiving niraparib maintenance in addition to standard therapy for USC may have an improved progression-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Participating sites include the primary site, Northwell Health Zucker Cancer Centre, and secondary site, Rutgers Cancer Institute of NJ. Females over the age of 18 with stage III, stage IV or platinum-sensitive recurrent USC will be recruited and enrolled based on inclusion\/exclusion criteria. 24 subjects will be enrolled during phase 1 and 21 subjects will be enrolled during phase 2, over a total of 3 years. Patients will receive an individualised dose of niraparib daily every 28 days per cycle for 1 year or until progression of disease. Follow-up of disease status will continue for 5 years poststudy treatment. This phase II clinical trial will employ a Simon two-stage minimax design to test the null hypothesis that the 1 year response rate is &lt;20% versus the alternative hypothesis that the 1 year response rate is \u226540%, with alpha=0.05\u2009and power=0.90.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was granted by Northwell Health Cancer Institute institutional review board (reference number: 19\u20130380) and PRMS. Alongside journal publications, results will be available publicly on completion of the study as approved by the sponsor investigator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCTN04080284<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087115","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:25:15Z","timestamp":1749097515000},"page":"e087115","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Maintenance with niraparib in patients with stage III, stage IV, chemo-na\u00efve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial"],"prefix":"10.1136","volume":"15","author":[{"given":"Marina","family":"Frimer","sequence":"first","affiliation":[{"name":"Feinstein Institutes for Medical Research, Manhasset, New York, USA"},{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle","family":"Katcher","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-2230","authenticated-orcid":false,"given":"Pegah","family":"Blustein","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sison","sequence":"additional","affiliation":[{"name":"Feinstein Institutes for Medical Research, Manhasset, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Nizam","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology of Middle Tennessee, TriStar Centennial Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Tymon-Rosario","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Feinstein Institutes for Medical Research, Manhasset, New York, USA"},{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Menzin","sequence":"additional","affiliation":[{"name":"Feinstein Institutes for Medical Research, Manhasset, New York, USA"},{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fidel","family":"Valea","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Scanlon","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill S","family":"Whyte","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Sakaris","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, South Shore University Hospital, Bay Shore, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Pereira","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Gynecologic Oncology, Lenox Hill Hospital, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine","family":"Villella","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Gynecologic Oncology, Lenox Hill Hospital, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-shin D","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Siebel","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Huntington Hospital, Greenlawn, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[{"name":"Pathology and Diagnostic Medicine, Foundation Medicine Inc, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Elvin","sequence":"additional","affiliation":[{"name":"Pathology and Diagnostic Medicine, Foundation Medicine Inc, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York, USA"},{"name":"Gynecologic Oncology, Zucker School of Medicine at Hofstra\/Northwell, Queens, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"John","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025121422144789000_15.6.e087115.1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27720"},{"key":"2025121422144789000_15.6.e087115.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03167"},{"key":"2025121422144789000_15.6.e087115.3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2015.12.034","article-title":"Germline mutations of the DNA repair pathways in uterine serous carcinoma","volume":"141","author":"Frimer","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2025121422144789000_15.6.e087115.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330"},{"key":"2025121422144789000_15.6.e087115.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0953"},{"key":"2025121422144789000_15.6.e087115.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"2025121422144789000_15.6.e087115.7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"DESTINY-PanTumor01 study group","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025121422144789000_15.6.e087115.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"2025121422144789000_15.6.e087115.9","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-003144"},{"key":"2025121422144789000_15.6.e087115.10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma","volume":"497","year":"2013","journal-title":"Nature New Biol"},{"key":"2025121422144789000_15.6.e087115.11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025121422144789000_15.6.e087115.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.11.028"},{"key":"2025121422144789000_15.6.e087115.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30559-9"},{"key":"2025121422144789000_15.6.e087115.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.036"},{"key":"2025121422144789000_15.6.e087115.15","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2025121422144789000_15.6.e087115.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121422144789000_15.6.e087115.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025121422144789000_15.6.e087115.18","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121422144789000_15.6.e087115.19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00433915"},{"key":"2025121422144789000_15.6.e087115.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"2025121422144789000_15.6.e087115.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.10.024"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:14:54Z","timestamp":1765779294000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-087115"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087115","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}